BIOMAT Database Logo BIOMAT Database Logo

Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. 1990

P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Service d'Hépatologie, Hôpital Beaujon, Clichy, France.

Pharmacokinetics, tolerance and biological effects of human recombinant gamma-interferon were studied in 12 patients with chronic active hepatitis B. Serum concentrations of gamma-interferon were measured by radioimmunoassay in four patients after a subcutaneous injection of 10 million U (0.5 mg); the peak serum concentration of gamma-interferon (29 +/- 7 U/ml) was reached after 5 to 8 hr and gamma-interferon remained detectable for 24 to 36 hr. Twelve patients received recombinant gamma-interferon, 2.5 to 10 million U daily, for 4 mo. All suffered from a dose-dependent, flulike syndrome similar to that induced by alpha-interferon. Recombinant gamma-interferon induced a marked increase of serum ALT and a significant decrease of serum hepatitis B virus-DNA. Serum hepatitis B virus-DNA disappeared in one patient during administration of recombinant gamma-interferon. Serum hepatitis B virus-DNA disappeared in four additional patients, and HBeAg disappeared in two patients during the 12 mo after administration of recombinant gamma-interferon. These results indicate that subcutaneous injection is suitable for administration of recombinant gamma-interferon and that recombinant gamma-interferon has an antiviral effect in patients with chronic active hepatitis B.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects.
April 1985, Gastroenterology,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon.
February 1990, Hepatology (Baltimore, Md.),
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
[Antiviral treatment of chronic active hepatitis B. Combination therapy with beta interferon and recombinant gamma interferon].
July 1988, Fortschritte der Medizin,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
June 1985, Cancer research,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
[Histological changes in 20 hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon-gamma treatment].
October 2001, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Effects of recombinant alpha interferon on chronic active hepatitis B: preliminary results.
January 1993, Gut,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Effects of recombinant human leukocyte interferon treatment of endogenous interferon production in patients with chronic type-B hepatitis.
February 1986, Journal of interferon research,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.
November 1988, Gastroenterology,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Randomised controlled trial of recombinant human interferon -alpha A for chronic active hepatitis B.
February 1990, Australian and New Zealand journal of medicine,
P Marcellin, and M A Loriot, and N Boyer, and M Martinot-Peignoux, and C Degott, and F Degos, and M Brandely, and B Lenfant, and J P Benhamou
Tolerance and antiviral effects of high-dose interferon-alpha B/D in patients with chronic hepatitis B.
August 1998, Digestive diseases and sciences,
Copied contents to your clipboard!